trending Market Intelligence /marketintelligence/en/news-insights/trending/goqfrw62x1dsozbddgd9va2 content esgSubNav
In This List

Genscript Biotech to invest $75M in China biologics center

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Genscript Biotech to invest $75M in China biologics center

Genscript Biotech Corp. plans to invest $75 million to set up a biologics clinical and commercial manufacturing center in Zhenjiang, China.

The company intends to use the facility for the production of clinical samples and commercialized biologics. The facility will include areas for the production, filling, quality control and cold chain logistics for biologics, warehouse facilities for raw and auxiliary materials, energy center and other purposes.

Genscript said the facility would allow for phases 1 to 3 clinical sample production and commercial production to meet local and foreign client demands. The total production capacity of the manufacturing center is estimated to reach 5,700 liters.

Jiangsu, China-based Genscript makes and sells life sciences research products and services.